Cilta-cel in R/R MM: ASCO 2024 Updates from CARTITUDE Trials

Opinion
Video

Hans Lee, MD, discusses recent updates presented at ASCO 2024 surrounding cilta-cel CAR T-cell therapy in relapsed/refractory multiple myeloma.

Video content above is prompted by the following questions:

  • Review the recent updates surrounding CAR T-cell therapy in R/R MM:
    • CARTITUDE-4 subgroup analysis
    • CARTITUDE-2 cohort A expansion subgroup
    • CARTITUDE-2 cohort D
  • What is the rationale for using CAR T-cell therapy in patients with R/R MM?
Recent Videos
9 Experts are featured in this series.
9 Experts are featured in this series.
2 experts are featured in this series.
9 Experts are featured in this series.
9 Experts are featured in this series.
4 KOLs are featured in this series.
4 KOLs are featured in this series.
4 KOLs are featured in this series.
4 KOLs are featured in this series.
9 Experts are featured in this series.
Related Content
Optimal Sequencing Between CAR T and Bispecifics in Multiple Myeloma

Optimal Sequencing Between CAR T and Bispecifics in Multiple Myeloma

ONCOLOGY Staff
November 20th 2024
Article

The use of CAR T-cell therapy and other sequencing options were discussed for patients with multiple myeloma.

Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

Mitigating AEs and Protecting QOL Following Talquetamab in Multiple Myeloma

Samantha Shenoy, NP, MSN
October 14th 2024
Podcast

Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

Survival data from the interim analysis of the phase 3 DREAMM-7 trial will be presented at the 2024 ASH Annual Meeting.

Belantamab Mafodotin Combo Significantly Improves OS in Multiple Myeloma

Russ Conroy
November 14th 2024
Article

Survival data from the interim analysis of the phase 3 DREAMM-7 trial will be presented at the 2024 ASH Annual Meeting.

James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

Exploring the Potential Role of JAK Inhibitors in Multiple Myeloma

James R. Berenson, MD, FACP
September 30th 2024
Podcast

James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

Data from the phase 3 AQUILA study support the applications for subcutaneous daratumumab in high-risk smoldering multiple myeloma.

FDA, EMA Receive Applications for Subcutaneous Daratumumab in Myeloma

Russ Conroy
November 8th 2024
Article

Data from the phase 3 AQUILA study support the applications for subcutaneous daratumumab in high-risk smoldering multiple myeloma.

The Hidden Danger Unveiling the Connection Between Multiple Myeloma and Pleural Effusion

The Hidden Danger Unveiling the Connection Between Multiple Myeloma and Pleural Effusion

FNU Fatima, MBBS;Faryal Arif, MBBS;Muhammad Hamza Gul, MBBS, MD;Neha Siddiqui, MBBS;Muhammad Zulqarnain, MBBS;Abdul Baseer Wardak, MBBS
November 8th 2024
Article

This case highlights the importance of early recognition and management of pleural effusion in patients with multiple myeloma and underscores the need for further research into optimal management strategies and underlying mechanisms.